Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus
Bayer on Wednesday announced plans to acquire Perfuse Therapeutics for as much as $2.45 billion, targeting a mid-stage drug candidate for eye disease as it looks to reinforce its ophthalmology unit. The German company is putting down $300 million upfront; future payouts will hinge on how the drug progresses through development, regulatory hurdles, and eventual sales.
